Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $735.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock Forecast
Analysts expect Sagimet Biosciences Inc. Series A Common Stock (SGMT) to earn -$1.25 per share in the fiscal year ending Dec 31, 2026. Of 12 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 9 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 1 | 8.3% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.25
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.35
- EPS consensus, revenue $13.18M
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.25 | -$1.52 to -$1.15 | 7 | N/A | N/A | 10 |
| Dec 31, 2027 | -$1.35 | -$2.43 to -$0.39 | 10 | $13.18M | N/A | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.29 for the quarter ending Dec 31, 2026 to -$0.27 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.29 | -$0.35 to -$0.22 | 14 | N/A | N/A | 13 |
| Mar 31, 2027 | -$0.27 | -$0.30 to -$0.22 | 4 | $2.96M | $930000 to $5.00M | 2 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 9 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.20.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.25 | -$1.12 | -$1.12 | -$1.16 | -$1.20 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.35 | -$1.30 | -$1.30 | -$1.37 | -$1.34 | N/A |
| Quarter ending Mar 31, 2027 | -$0.27 | -$0.29 | -$0.29 | -$0.34 | -$0.33 | N/A |
Frequently Asked Questions About SGMT
What is the SGMT stock forecast?
Consensus analyst estimates put Sagimet Biosciences Inc. Series A Common Stock's EPS at -$1.25 for the fiscal year ending Dec 31, 2026. The consensus rating from 12 analysts is Buy.
How do analysts rate SGMT stock?
Of 12 analysts covering Sagimet Biosciences Inc. Series A Common Stock, 2 rate it Strong Buy, 9 Buy, 0 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from SGMT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.25, with estimates from -$1.52 to -$1.15 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.35, with estimates from -$2.43 to -$0.39 from 10 analysts.
What revenue do analysts expect from Sagimet Biosciences Inc. Series A Common Stock next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $13.18M.
How many analysts cover SGMT?
12 analysts rate Sagimet Biosciences Inc. Series A Common Stock stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
SGMT pages: Overview, Earnings, Forecast, Financials, Competitors